Last reviewed 2026-05-14 · How we verify

Abiraterone: Treatment C

CYP17 inhibitor

CYP17 inhibitor Used for Prostate cancer.

At a glance

Mechanism of action

Abiraterone acetate is a synthetic, irreversible inhibitor of CYP17, a key enzyme in the biosynthesis of androgens.

Approved indications

• Prostate cancer

Common side effects

• Fatigue
• Hypertension
• Diarrhea
• Nausea
• Muscle spasm

Key clinical trials

• A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer (PHASE1)
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial (PHASE2)
• Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (PHASE1, PHASE2)
• Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial (PHASE2)
• A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer (PHASE3)
• Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies (PHASE1, PHASE2)
• Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer (PHASE1)
• Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Abiraterone: Treatment C CI brief — competitive landscape report
• Abiraterone: Treatment C updates RSS · CI watch RSS
• Janssen Research & Development, LLC portfolio CI